1Department of Medical Oncology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea
2Department of Internal Medicine, Seoul Medical Center, Seoul, Korea
3Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea
4Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea
5Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
6Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
7Ewha Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea
8Department of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Korea
9College of Nursing, Gachon University, Incheon, Korea
Copyright © 2019 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Characteristic | No. of patients (n=336) |
|---|---|
| Age, median (range, yr) | 66 (20-94) |
| Sex | |
| Male | 177 (52.7) |
| Female | 159 (47.3) |
| ECOG | |
| 1/2 | 133 (39.6) |
| 3/4 | 203 (60.4) |
| Diagnosis | |
| Hepato-pancreato-biliary cancer | 88 (26.2) |
| Lung cancer | 78 (23.2) |
| Gastrointestinal cancer | 67 (19.9) |
| Breast cancer | 34 (10.1) |
| Genitourinary tract cancer | 26 (7.7) |
| Head and neck cancer | 19 (5.7) |
| Others | 24 (7.1) |
| Treatment status | |
| Initially diagnosed with terminal cancer | 17 (5.1) |
| Under anticancer treatment | 53 (15.8) |
| After disease progression | 127 (37.8) |
| Hospice care | 138 (41.1) |
| Follow-up status | |
| During follow-up | 140 (41.9) |
| Transferred from other departments | 91 (27.3) |
| Transferred from other hospitals | 103 (30.8) |
| Life expectancy (wk) | 10.6±7.3 |
| Type of barrier | No. (%) (n=181) |
|---|---|
| Families’ reluctance and/or conflict | 90 (49.7) |
| Lack of rapport with patients | 81 (44.8) |
| Patients’ denial or avoidance of the prognosis | 62 (34.3) |
| Lack of time for discussing the POLST | 41 (22.7) |
| Fear of depriving patients’ hope or of abandonment | 39 (21.5) |
| Uncertainty of cancer prognostication | 38 (21.0) |
| Uncertainty of the right time for POLST discussion | 30 (16.6) |
| Type of barrier | No. (%) (n=63) |
|---|---|
| Lack of knowledge/Understanding | 41 (65.1) |
| Lack of knowledge about POLST | 26 (41.3) |
| Lack of understanding of the POLST paradigm | 26 (41.3) |
| Emotional discomfort | 40 (63.5) |
| Fear of giving-up or being abandoned by their physicians | 19 (30.2) |
| Fear of bad things happening after a POLST documentation | 28 (44.4) |
| Discomfort in talking about death | 19 (30.2) |
| Refusal or difficulty in decision-making | 42 (66.7) |
| Trust for family as a surrogate decision-maker | 28 (44.4) |
| Trust for a physician as a surrogate decision-maker | 22 (34.9) |
| Denial of prognosis | 9 (14.3) |
ECOG, Eastern Cooperative Oncology Group.
POLST, Physician’s Order for Life-sustaining Treatment.
POLST, Physician’s Order for Life-sustaining Treatment.
